Novartis achieves record results in 2009
- Details
- Category: Novartis
Novartis ended 2009 strongly, delivering double-digit net sales and earnings growth that reflected operational progress in all divisions and more favorable currency conditions over the 2008 period.
Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany has announced that an independent Data Safety and Monitoring Board (DSMB) has completed an interim analysis of a phase II trial (the LIPLONG study) of the company's long-acting recombinant factor VIII, BAY79-4980. The DSMB concluded that the study will not be able to achieve the predetermined efficacy endpoint (non-inferiority). No safety concerns were raised.
Bayer to discontinue the LIPLONG study
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany has announced that an independent Data Safety and Monitoring Board (DSMB) has completed an interim analysis of a phase II trial (the LIPLONG study) of the company's long-acting recombinant factor VIII, BAY79-4980. The DSMB concluded that the study will not be able to achieve the predetermined efficacy endpoint (non-inferiority). No safety concerns were raised.
Novo Nordisk receives approval for Victoza® in Japan
- Details
- Category: Novo Nordisk
Novo Nordisk announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes.
Sanofi-aventis and employees unite for the victims of Haiti
- Details
- Category: Sanofi
In the face of the unprecedented earthquake that hit the island of Haiti, sanofi-aventis has committed 1 million Euros in financial aid to long-term reconstruction initiatives and the rehabilitation of the population of Haiti.
Three new Novartis medicines approved in Japan
- Details
- Category: Novartis
Patients in Japan will benefit from the approval of three new Novartis medicines - Equa® (vildagliptin), marketed as Galvus® in the European Union, for the treatment of type 2 diabetes, Exforge® (valsartan/amlodipine) for high blood pressure, and Afinitor® (everolimus) for advanced kidney cancer. These approvals reinforce the strong commitment of Novartis to helping patients in Japan, the company's second-largest pharmaceutical market.
Bristol-Myers Squibb supporting efforts to help survivors
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb is joining the world community in providing immediate help for survivors of the massive earthquake that struck Haiti on January 12. The company has already shipped a large donation of antibiotics through Project Hope, an organization providing direct relief to disaster victims.
More Pharma News ...
- Lilly Sends Relief to Haiti Earthquake Victims
- Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
- Novartis providing equivalent of over USD 2.5 million for victims of Haiti earthquake
- Amgen Donates $2 Million, Establishes Earthquake Relief Program
- Abbott to Provide $1 Million in Funding, Products to Help Address Health Needs in Haiti
- Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue
- FDA approves ACTEMRA for the treatment of moderately to severely active rheumatoid arthritis